A Study of LY3502970 in Healthy Overweight and Obese Participants

Lilly logo

Lilly

Status and phase

Completed
Phase 1

Conditions

Obese
Healthy

Treatments

Drug: LY3502970

Study type

Interventional

Funder types

Industry

Identifiers

NCT05313802
18453
J2A-MC-GZGK (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.

Enrollment

72 patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Participants with stable body weight for at least one month prior to randomization.
  • Participants with body mass index (BMI) of greater than or equal to (≥) 27.0 kilograms per meter squared (kg/m²)
  • Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential

Exclusion criteria

  • Have known allergies to LY3502970 or other glucagon-like peptide-1 Receptor Agonists (GLP-1 RA) analogs
  • Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders
  • Have any type of diabetes with hemoglobin A1c (HbA1c) ≥6.5 %

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

72 participants in 3 patient groups

LY3502970 (Dose Level 1)
Experimental group
Description:
LY3502970 administered orally.
Treatment:
Drug: LY3502970
LY3502970 (Dose Level 2)
Experimental group
Description:
LY3502970 administered orally.
Treatment:
Drug: LY3502970
LY3502970 (Dose Level 3)
Experimental group
Description:
LY3502970 administered orally.
Treatment:
Drug: LY3502970

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems